- Home
- VRCA
as of 12-12-2025 3:41pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 32.7M | IPO Year: | 2018 |
| Target Price: | N/A | AVG Volume (30 days): | 399.9K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.28 - $9.82 | Next Earning Date: | 11-14-2025 |
| Revenue: | $30,829,000 | Revenue Growth: | 234.73% |
| Revenue Growth (this year): | 373.65% | Revenue Growth (next year): | -24.48% |
AI-Powered VRCA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Verrica Pharmaceuticals Inc. (VRCA)
Director, 10% Owner
Avg Cost/Share
$4.24
Shares
4,126,142
Total Value
$17,505,157.44
Owned After
3,958,189
Interim CFO
Avg Cost/Share
$4.24
Shares
3,536
Total Value
$15,001.48
Owned After
8,962
SEC Form 4
CEO and President
Avg Cost/Share
$4.24
Shares
94,311
Total Value
$400,114.42
Owned After
182,593
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$4.24
Shares
10,000
Total Value
$42,425.00
Owned After
21,000
SEC Form 4
Avg Cost/Share
$4.24
Shares
2,357
Total Value
$9,999.57
Owned After
2,357
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Manning Paul B | VRCA | Director, 10% Owner | Nov 25, 2025 | Buy | $4.24 | 4,126,142 | $17,505,157.44 | 3,958,189 | |
| Kirby John J. | VRCA | Interim CFO | Nov 25, 2025 | Buy | $4.24 | 3,536 | $15,001.48 | 8,962 | |
| Rieger Jayson | VRCA | CEO and President | Nov 25, 2025 | Buy | $4.24 | 94,311 | $400,114.42 | 182,593 | |
| Zawitz David | VRCA | Chief Operating Officer | Nov 25, 2025 | Buy | $4.24 | 10,000 | $42,425.00 | 21,000 | |
| Rosenberg Noah L. | VRCA | CMO | Nov 25, 2025 | Buy | $4.24 | 2,357 | $9,999.57 | 2,357 |
Compare VRCA vs Leading Stocks
See how VRCA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.